Literature DB >> 17016527

Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses.

.   

Abstract

BACKGROUND: The Canadian Glaucoma Study is a multicentered, prospective longitudinal study designed to study a variety of systemic risk factors for the progression of open-angle glaucoma under a standardised interventional protocol for intraocular pressure (IOP) control.
METHODS: Newly or previously diagnosed patients with early to moderate open-angle glaucoma were recruited consecutively from 5 hospital-based university departments. Baseline parameters, including an assessment of peripheral vasospasm, haematologic, coagulation, and immunopathologic variables were obtained. Newly diagnosed patients were targeted for a >or=30% reduction in IOP, whereas previously diagnosed patients entered the study at a physician-defined target IOP. After baseline examinations, patients were followed at 4-month intervals with standard automated perimetry, short-wavelength automated perimetry, and confocal scanning laser tomography, and at 28-32-month intervals with stereo disc photography. If the patient had visual field progression with standard automated perimetry, a further >or=20% reduction in IOP was mandated. A standardized IOP treatment protocol, ranging from topical monotherapy to filtration surgery, was implemented.
RESULTS: A total of 258 patients (131 [corrected] men and 127 [corrected] women, median age 65.0 years) were enrolled. Baseline median values for visual acuity, visual field mean deviation, untreated IOP, and refractive error were 0.10 logMAR, -4.04 dB, 25.0 mm Hg, and 0.00 D, respectively. Approximately 30% of the patients were hypertensive, 16% had cardiovascular disease, 9% thyroid disease, 9% diabetes, 14% migraine, and 19% were smokers. The median follow-up was 5.3 years, with 148 (57.0%) and 51 (19.8%) patients completing >or=5 and >or=7 years follow-up, respectively. The cumulative visual field progression rate at 2, 4, 6, and 8 years was 11.3%, 21.5%, 33.1%, and 43.5%, respectively.
INTERPRETATION: We describe the study design and baseline patient characteristics of the Canadian Glaucoma Study and present some preliminary results. This long and close follow-up of a large group of patients will reveal the importance of several systemic factors for the progression of glaucoma.

Entities:  

Mesh:

Year:  2006        PMID: 17016527     DOI: 10.1139/i06-057

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  6 in total

1.  Spatial pattern of glaucomatous visual field loss obtained with regionally condensed stimulus arrangements.

Authors:  Ulrich Schiefer; Eleni Papageorgiou; Pamela A Sample; John P Pascual; Bettina Selig; Elke Krapp; Jens Paetzold
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

2.  Are rates of vision loss in patients in English glaucoma clinics slowing down over time? Trends from a decade of data.

Authors:  T Boodhna; L J Saunders; D P Crabb
Journal:  Eye (Lond)       Date:  2015-08-28       Impact factor: 3.775

Review 3.  Medical interventions for primary open angle glaucoma and ocular hypertension.

Authors:  C Vass; C Hirn; T Sycha; O Findl; P Bauer; L Schmetterer
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

Review 4.  Practical recommendations for measuring rates of visual field change in glaucoma.

Authors:  B C Chauhan; D F Garway-Heath; F J Goñi; L Rossetti; B Bengtsson; A C Viswanathan; A Heijl
Journal:  Br J Ophthalmol       Date:  2008-01-22       Impact factor: 4.638

5.  Specification of progression in glaucomatous visual field loss, applying locally condensed stimulus arrangements.

Authors:  Jukka Nevalainen; Jens Paetzold; Eleni Papageorgiou; Pamela A Sample; John P Pascual; Elke Krapp; Bettina Selig; Reinhard Vonthein; Ulrich Schiefer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-29       Impact factor: 3.117

6.  Objective Quantification of Spontaneous Retinal Venous Pulsations Using a Novel Tablet-Based Ophthalmoscope.

Authors:  Sahar Shariflou; Ashish Agar; Kathryn Rose; Christopher Bowd; S Mojtaba Golzan
Journal:  Transl Vis Sci Technol       Date:  2020-03-18       Impact factor: 3.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.